HealthCore And AstraZeneca Big Data Initiative Pushes Ahead, But Will Lack of Trust Deter Additional Partners?
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca and HealthCore, a subsidiary of Wellpoint, are halfway through a four-year agreement to study the effectiveness and economics of marketed drugs using real world evidence. The collaboration is making progress, but reaching some goals has been a challenge, says HealthCore CEO Marcus Wilson
You may also be interested in...
Boehringer/WellPoint Outcomes Research To Inform Pradaxa Treatment
The study in non-valvular atrial fibrillation patients is the first project to launch under a five-year research agreement between Boehringer Ingelheim and WellPoint.
AstraZeneca, HealthCore Launch Outcomes Data Project, Seek Multi-Stakeholder Consortium
AstraZeneca and HealthCore, WellPoint's clinical outcomes research unit, have begun an evidence-development partnership that will focus on "real world" outcomes data in chronic ailments such as diabetes, cardiovascular disease and dyslipidemia.
WellPoint Plans To Seek Pharma Partners For Outcomes-Based Contracting: An Interview With WellPoint's Brian Sweet
In an interview, "The Pink Sheet" talked to WellPoint Chief Pharmacy Officer Brian Sweet about the near-to-mid-term outlook for outcomes-based agreements between payers and drug manufacturers, including initiatives WellPoint is taking to work differently with biopharma (1"The Pink Sheet," May 24, 2010)